Bank of America’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,319,669
| Closed | -$172K | – | 7292 |
|
|
2025
Q3 | $172K | Buy |
1,319,669
+177,956
| +16% | +$24.4K | ﹤0.01% | 6354 |
|
|
2025
Q2 | $273K | Sell |
1,141,713
-5,300
| -0.5% | -$1.42K | ﹤0.01% | 6040 |
|
|
2025
Q1 | $226K | Sell |
1,147,013
-1,715,317
| -60% | -$888K | ﹤0.01% | 6105 |
|
|
2024
Q4 | $1.54M | Sell |
2,862,330
-1,790,995
| -38% | -$1.31M | ﹤0.01% | 4668 |
|
|
2024
Q3 | $4.42M | Hold |
4,653,325
| – | – | ﹤0.01% | 3849 |
|
|
2024
Q2 | $4.53M | Sell |
4,653,325
-14,462
| -0.3% | -$15.9K | ﹤0.01% | 3699 |
|
|
2024
Q1 | $7.38M | Sell |
4,667,787
-30,167
| -0.6% | -$36.4K | ﹤0.01% | 3278 |
|
|
2023
Q4 | $3.73M | Buy |
4,697,954
+829
| +0% | +$467 | ﹤0.01% | 3797 |
|
|
2023
Q3 | $3.66M | Sell |
4,697,125
-1,294
| -0% | -$1.09K | ﹤0.01% | 3690 |
|
|
2023
Q2 | $4.35M | Sell |
4,698,419
-703,291
| -13% | -$839K | ﹤0.01% | 3544 |
|
|
2023
Q1 | $5.89M | Buy |
5,401,710
+663,098
| +14% | +$1.03M | ﹤0.01% | 3386 |
|
|
2022
Q4 | $6.92M | Buy |
4,738,612
+3,703,418
| +358% | +$6M | ﹤0.01% | 3066 |
|
|
2022
Q3 | $1.11M | Buy |
1,035,194
+43,750
| +4% | +$80.4K | ﹤0.01% | 4808 |
|
|
2022
Q2 | $1.69M | Buy |
991,444
+467,232
| +89% | +$803K | ﹤0.01% | 4457 |
|
|
2022
Q1 | $1.08M | Sell |
524,212
-13,899
| -3% | -$37.5K | ﹤0.01% | 5157 |
|
|
2021
Q4 | $2.02M | Sell |
538,111
-193,984
| -26% | -$883K | ﹤0.01% | 4549 |
|
|
2021
Q3 | $3.79M | Buy |
732,095
+719,108
| +5,537% | +$3.23M | ﹤0.01% | 3835 |
|
|
2021
Q2 | $55K | Sell |
12,987
-342,067
| -96% | -$1.66M | ﹤0.01% | 6788 |
|
|
2021
Q1 | $1.89M | Buy |
355,054
+352,706
| +15,022% | +$2.02M | ﹤0.01% | 4316 |
|
|
2020
Q4 | $13K | Buy |
2,348
+780
| +50% | +$4.24K | ﹤0.01% | 6672 |
|
|
2020
Q3 | $13K | Sell |
1,568
-622
| -28% | -$5.44K | ﹤0.01% | 6375 |
|
|
2020
Q2 | $22K | Sell |
2,190
-115
| -5% | -$722 | ﹤0.01% | 6236 |
|
|
2020
Q1 | $6K | Sell |
2,305
-2,917
| -56% | -$9.68K | ﹤0.01% | 6459 |
|
|
2019
Q4 | $6K | Buy |
+5,222
| New | +$5.57K | ﹤0.01% | 6729 |
|
|
2019
Q3 | – | Sell |
-6,700
| Closed | -$26K | – | 7224 |
|
|
2019
Q2 | $26K | Buy |
6,700
+6,433
| +2,409% | +$26.2K | ﹤0.01% | 6507 |
|
|
2019
Q1 | $1K | Sell |
267
-901
| -77% | -$4.2K | ﹤0.01% | 6955 |
|
|
2018
Q4 | $6K | Buy |
1,168
+701
| +150% | +$5.17K | ﹤0.01% | 6724 |
|
|
2018
Q3 | $6K | Sell |
467
-3,439
| -88% | -$36.1K | ﹤0.01% | 6775 |
|
|
2018
Q2 | $46K | Sell |
3,906
-1,965
| -33% | -$24.5K | ﹤0.01% | 6183 |
|
|
2018
Q1 | $66K | Sell |
5,871
-6,784
| -54% | -$59.4K | ﹤0.01% | 5919 |
|
|
2017
Q4 | $85K | Buy |
12,655
+11,917
| +1,615% | +$92K | ﹤0.01% | 5815 |
|
|
2017
Q3 | $6K | Buy |
738
+604
| +451% | +$3.77K | ﹤0.01% | 6664 |
|
|
2017
Q2 | $1K | Buy |
+134
| New | +$700 | ﹤0.01% | 6793 |
|
|
2016
Q3 | – | Sell |
-16,093
| Closed | -$131K | – | 7071 |
|
|
2016
Q2 | $131K | Buy |
16,093
+15,740
| +4,459% | +$148K | ﹤0.01% | 5403 |
|
|
2016
Q1 | $3K | Buy |
+353
| New | +$2.89K | ﹤0.01% | 6691 |
|
|
2015
Q3 | – | Sell |
-200
| Closed | -$4K | – | 7168 |
|
|
2015
Q2 | $4K | Buy |
+200
| New | +$3.43K | ﹤0.01% | 6870 |
|
Other funds holding ADAP
JAIC
EF
RG
XT
Bank of America's ADAP Position: Q4 2025 in Review
Bank of America sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 1,319,669 shares — an estimated $172K sold.
Bank of America first reported a position in ADAP in Q2 2015 and held it in 36 quarters. The position peaked at $7.38M in Q1 2024. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.
- Bank of America reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
- Bank of America sold 1,319,669 Adaptimmune Therapeutics shares in Q4 2025, an estimated $172K.
- Bank of America first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 36 quarters.
- Bank of America's Adaptimmune Therapeutics position peaked at $7.38M in Q1 2024.
- 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.
Based on Bank of America's 13F filing for Q4 2025, filed 17 Feb 2026.